ALLK Allakos Therapeutics: Forward P/S Multiple
Allakos Inc. focuses on the therapy of allergic pathologies and maintains a high dependency on early trial outcomes. The projected P/S ratio reflects current valuation dynamics, where represents the latest metric reading. Growth potential is driven by leading immunologists with extensive research resources, as well as a fabless model utilizing top-tier US contract manufacturers.
Metric breakdowns and analytics for allakos.com (ALLK)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
ALLK - Final Profit|Projected Future Earnings Allakos Inc.|ALLK - Business Payback Period|Future Price to Earnings Allakos|ALLK - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple ALLK|ALLK - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Allakos|ALLK - Net earnings per share for the last four quarters|Quarterly EPS earnings growth allakos.com|ALLK - Earnings growth in current year|Net earnings per share growth forecast for next year Allakos Inc.
- sales revenue and business income indicators:
Fundamental company analysis:ALLK (Allakos Therapeutics)
This indicator assesses the asset's market value relative to projected sales volumes, allowing for the determination of the premium paid for future revenue growth. By analyzing the forward P/S of the firm, an investor sees the ratio of market capitalization to expected revenues, which is critically important for Allakos Inc. (ALLK) as it scales mast cell therapy into the extensive market for treating chronic inflammatory diseases.
Competitor analysis
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA - Forward P/S Multiple|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|IMVT (immunovant.com) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Kiniksa|Price-to-Projected Revenue Ratio GRFS|Forward P/S Multiple ADPT|Forward P/S Multiple Celldex Corp (CLDX)|Price-to-Projected Revenue Ratio Aurinia Pharmaceuticals AUPH|Forward P/S Multiple biocryst.com BCRX|VERA - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Dianthus Therapeutics Inc|Pharvaris Corp (PHVS) - Price-to-Projected Revenue Ratio|ABCL - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple TRML|PGEN: Forward Price to Sales|Forward P/S Multiple PHAR|Market Cap to Expected Sales Ratio Nektar Therapeutics Inc|Price-to-Projected Revenue Ratio Upstream Bio Corp UPB|ZBIO: Market Cap to Projected Revenue|Immunome, Inc. - Forward P/S Multiple|gossamerbio.com (GOSS) - Forward Price-to-Revenue Multiple|KALV (KalVista Pharmaceuticals, Inc.) - Forward Price-to-Revenue Multiple|SEPN - Market Cap to Expected Sales Ratio|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|Forward P/S Multiple Savara Pharma|Price-to-Projected Revenue Ratio Rigel Pharmaceuticals (RIGL)|Price-to-Projected Revenue Ratio ANAB (anaptysbio.com)|Price-to-Projected Revenue Ratio Astria Therapeutics, Inc. ATXS|enGene Holdings Inc - Price-to-Projected Revenue Ratio|RAPT - Price-to-Projected Revenue Ratio|JBIO - Forward P/S Multiple|Aclaris Therapeutics (ACRS) - Price-to-Projected Revenue Ratio|Future Price to Revenue KYTX (kyvernatx.com)|TLSA (Tiziana Life Sciences Ltd) - Forward P/S Multiple|CABA: Forward Price to Sales|Forward P/S Multiple VTYX|Forward P/S Multiple Theratechnologies, Inc (THTX)|Price-to-Projected Revenue Ratio Avalo Therapeutics, Inc AVTX|Forward Price to Sales ELDN|AGEN - Price-to-Projected Revenue Ratio|Climb Bio Inc. (CLYM) - Forward Price-to-Revenue Multiple|ZURA: Forward P/S Multiple|aTyr Pharmaceuticals (ATYR) - Forward P/S Multiple|Forward Price-to-Revenue Multiple ADAG|IMA: Forward Price to Sales|Forward P/S Multiple STTK|Market Cap to Expected Sales Ratio equilliumbio.com|Price-to-Projected Revenue Ratio Connect Biopharma Holdings Limited CNTB|IMUX - Forward Price-to-Revenue Multiple|ATRA - Price-to-Projected Revenue Ratio|InflaRx N.V. (IFRX) - Forward Price-to-Revenue Multiple|XFOR (X4 Pharmaceuticals, Inc.) - Forward Price-to-Revenue Multiple|Adicet Bio, Inc. (ACET) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Celularity Inc|Market Cap to Projected Revenue INMB (INmune Bio Corporation)|Forward P/S Multiple BRNS|KZR - Market Cap to Future Revenue Ratio|Forward P/S Multiple SABS (SAB Biotherapeutics, Inc.)|Forward P/S Multiple Akari Therapeutics PLC AKTX|ENLV - Price-to-Projected Revenue Ratio|QTTB: Price-to-Projected Revenue Ratio|GeoVax Labs, Inc. (GOVX) - Price-to-Projected Revenue Ratio|EDSA (edesabiotech.com) - Price-to-Projected Revenue Ratio|IBIO (iBio) - Forward P/S Multiple|Forward P/S Multiple Carisma Tx|Price-to-Projected Revenue Ratio XTL Biopharmaceuticals, Ltd. (XTLB)|Forward P/S Multiple boltbio.com (BOLT)|Price-to-Projected Revenue Ratio HCW Biologics HCWB|Aptevo Therapeutics, Inc. (APVO) - Market Cap to Future Revenue Ratio|AIM - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Aditxt ADTX|GRI (GRI Bio Corp) - Forward Price-to-Revenue Multiple|XORTX Corp - Forward Price to Sales|HIND (Vyome Holdings Inc) - Forward P/S Multiple|revbiosciences.com (REVB) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Indaptus Therapeutics, Inc. (INDP)|Scinai Immunotherapeutics Ltd - Market Cap to Projected Revenue|Forward P/S Multiple CALI (CalciMedica)|AFMD - Forward Price-to-Revenue Multiple|HOOK: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio IGM Biosciences, Inc. IGMS|ITOS: Forward P/S Multiple|Ocean Biomedical Inc (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Price-to-Projected Revenue Ratio THRD
